Skip to main content

Table 3 Developmental and behavioral features of patients with PMS in our cohort as compared to the literature

From: A 29 Mainland Chinese cohort of patients with Phelan–McDermid syndrome: genotype–phenotype correlations and the role of SHANK3 haploinsufficiency in the important phenotypes

Feature

N

Total

%

Literature frequencya (%)

Developmental/neurological

 Speech (age ≥ 3)

  Absent speech

11

20

55

 

  Sentences

9

20

45

 

 Walk independently (age ≥ 3)

20

20

100

 

 DD/ID

23

26

88

 

 Any type of seizures (including febrile seizures)

7

29

24

14–41

 Overheats or turns red easily

5

29

17

68b

 Decreased perspiration

2

29

7

60b

 Overly sensitive to touch

5

29

17

46b

 Increased pain tolerance

18

29

62

29–100

 Arachnoid cyst

4

29

14

19b

 Hypotonia

24

29

83

29–100

 Gait abnormalities

16

29

55

93c

Behavioral features

 Autism spectrum disorder (age ≥ 3)

16

20

80

31b

 Impulsiveness

22

29

76

47c

 Chewing difficulties (difficulty with eating)

9

29

31

58c

 Biting (self or others)

9

29

30

46b

 Hair pulling

9

29

31

41b

 Excessive screaming

5

29

17

31b

 Aggressive behavior

9

29

30

28b

 Nonstop crying (crying non-stop for 3 h)

13

29

45

21b

 Hyperactivity

24

29

83

47c

 Self-injury

3

29

10

 

 Pica

3

29

10

 

 Repetitive behaviors

20

29

69

100c

 Sleep disturbance

7

29

24

41–46

 Regression

13

29

45

65d

Other clinical features

 Gastroesophageal reflux

2

29

7

> 25–44

 Diarrhea/constipation

7

29

23

38–41

 Congenital heart defect

4

29

14

3c

 Genital anomalies

1

23

4

5b

 Eczema

8

29

28

18d

 Enzyme deficiency

0

29

0

4b

 Immune deficiency

1

29

3

12b

 Recurring upper respiratory tract infections

6

29

21

29–100

 Hearing loss

1

29

3

3d

 Allergies

5

29

17

 

 Asthma

1

29

3

 

 Renal abnormalities

3

21

14

17–38

 Lymphedema

0

29

0

22–29

 Hypothyroid

0

29

0

6b

 Diabetes

0

29

0

2b

 Vitiligo

0

29

0

3c

  1. aFrequencies based on the literature review available [27]
  2. bFrequencies available in the clinical and genomic evaluation of 201 patients with PMS [23]
  3. cFrequencies based on a Brazilian cohort of individuals with PMS [22]
  4. dFrequency based on the analysis of PMS individuals carrying SHANK3 point mutations [28]
  5. eFrequencies based on a previous report [5]